Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Eisai Seeks Marketing Approvals for Anticancer Drug in Europe, U.S.

August 18, 2014 10:56 am | News | Comments

Eisai Co. Ltd. announced that it has submitted applications to regulatory authorities in the U.S. and Europe for marketing approval of its novel in-house developed anticancer agent lenvatinib mesylate as a treatment for progressive radioiodine-refractory differentiated thyroid cancer. Read more...

TOPICS:

Microchip Tracks Cancer Cell Migration

August 18, 2014 10:50 am | News | Comments

Using a microengineered device that acts as an obstacle course for cells that leaves just enough space for the cells to weave their way through, researchers have shed new light on a cellular metamorphosis thought to play a role in tumor cell invasion throughout the body. Read more...

TOPICS:

Ebola Quarantine Escapees Return

August 18, 2014 10:39 am | by Jonathan Paye-Layleh, Associated Press | News | Comments

Some of the people who fled an Ebola quarantine center in a Liberian slum when it was looted over the weekend are again under observation at a hospital Monday, as authorities struggle to contain the spread of an Ebola outbreak in West Africa. Read more...

TOPICS:
Advertisement

Coherus' Humira Biosimilar Hits Primary Endpoint

August 15, 2014 2:28 pm | News | Comments

Coherus BioSciences Inc. announced that CHS-1420, its proposed biosimilar of adalimumab (Humira), met the primary endpoint in a pivotal clinical pharmacokinetic similarity study that compared CHS-1420 to Humira in healthy subjects. Read more...   

TOPICS:

FDA Committee Backs BI's COPD Drug

August 15, 2014 2:22 pm | News | Comments

Boehringer Ingelheim announced that the FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted that existing data supports approval of investigational tiotropium bromide inhalation spray for long-term, once-daily maintenance treatment of bronchospasm associated with COPD. Read more...

TOPICS:

Isis Earns $2M from the Advancement of SMA Drug

August 15, 2014 2:07 pm | News | Comments

Isis Pharmaceuticals Inc. announced that it has earned a $2 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy. Read more...    

TOPICS:

Watch Yourself: Device Data May Improve Parkinson's Research, Monitoring

August 15, 2014 2:01 pm | Videos | Comments

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Intel Corporation announced a collaboration aimed at improving research and treatment for Parkinson’s disease. Read more...                  

TOPICS:

New Focus on Drugs Made in Tobacco Plants

August 15, 2014 1:47 pm | by Malcolm Ritter, AP Science Writer | News | Comments

It's an eye-catching angle in the story of an experimental treatment for Ebola: The drug comes from tobacco plants that were turned into living pharmaceutical factories. Using plants this way- sometimes called "pharming"- can produce complex and valuable proteins for medicines. Read more...

TOPICS:
Advertisement

10 Things You Might Not Know About Ebola

August 15, 2014 1:09 pm | by Christina Jakubowski, News Editor | News | Comments

The 2014 outbreak of Ebola virus in West Africa has the world on high alert. Currently deemed an international public health emergency by the WHO, the virus has racked up more than 1,060 deaths and sickened 1,975 – making it the deadliest Ebola outbreak ever.

TOPICS:

Mallinckrodt Acquires Questcor Pharmaceuticals

August 15, 2014 10:27 am | News | Comments

Mallinckrodt plc, a leading global specialty pharmaceutical company, announced that it has completed its acquisition of Questcor Pharmaceuticals Inc. in a cash and stock transaction valued at approximately $5.8 billion following strong approval by both Mallinckrodt and Questcor shareholders. Read more...

TOPICS:

FDA Accepts BLA for Meningococcal Vaccine

August 15, 2014 10:18 am | News | Comments

Pfizer Inc. announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for bivalent recombinant LP2086, the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds. Read more...

TOPICS:

HIV Patients in Developing Countries Face New Health Threats

August 15, 2014 10:11 am | News | Comments

Health care systems that keep HIV patients from dying early in low- and middle-income nations need urgently to be repurposed to treat the chronic diseases that many of these patients now have, according to recommendations resulting from a multidisciplinary conference sponsored by the National Institutes of Health. Read more...

TOPICS:

FDA Approves Avastin in Cervical Cancer

August 15, 2014 10:00 am | News | Comments

Roche announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix. Read more...

TOPICS:

Chikungunya Vaccine Induces Robust Antibody Response

August 15, 2014 9:55 am | News | Comments

An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult volunteers who participated in a recent early-stage clinical trial conducted by researchers at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Read more...

TOPICS:

Unlocking the Power of Big Data in R&D, Part One

August 15, 2014 9:09 am | by Sharon Benzeno, PhD, MBA, Senior Director, Business Development Bioinformatics, Elsevier | Articles | Comments

Big data promises big insights for drug discovery and development, but its intrinsic value will be unlocked only if R&D organizations have the tools to make sense of it. Part 1 of this two-part article looks at how new models are changing the world of R&D. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading